/

VRDN

Viridian Therapeutics, Inc.Pre-market

18.30−0.36 −1.93%USD

NasdaqCM · as of Oct 12, 16:00 ET · 15m delay

Open

19.00

Prev close

18.66

Day range

18.2119.19

52-week range

13.1834.29

Volume

1.95M1.13×

Mkt cap

2.07B

P/E ttm

—

Fwd P/E

-6.68

EPS ttm

-3.39

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−46.63%

Price Chart

Yahoo Finance · delayed

VRDNOct 12, 2026O 19.00H 19.18L 18.21C 18.30−0.36 (−1.93%)Vol 1.95M

SMA 5021.83
SMA 20022.42

1Y change −12.82% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

VRDN Viridian Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −3.68%
1 month: −13.84%
3 months: −3.63%
6 months: +23.65%
Year to date: −41.20%
1 year: −12.82%

Valuation & ownership

Market cap: 2.07B
Enterprise value: 1.43B
P/E (ttm): —
Forward P/E: -6.68
PEG ratio: —
Price / book: 3.67
Price / sales (ttm): 29.15
EV / EBITDA: -3.54
EPS (ttm): -3.39
EPS (forward): -2.74
Beta (5y monthly): 1.10
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 113.29M
Float: 100.65M
Short % of float: 16.43%
Short ratio (days): 10.90
Held by insiders: 0.17%
Held by institutions: 126.76%
Avg volume (3m): 1.72M
50-day average: 21.83
200-day average: 22.42
52-week change: −12.82%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 33.1
vs 50-day SMA: −16.18%
vs 200-day SMA: −18.37%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 4.88%
Realised vol (20d, ann.): 44.2%
From 52-week high: −46.63%
From 52-week low: +38.85%

ANR

Analyst Consensus

16 analysts

Consensus

Strong buy

1.18 on a 1 (strong buy) – 5 (sell) scale

Mean target

36.75

+100.82% implied

Low 22.00Median 36.50High 50.00

Recommendation trend

Now17 / 0 / 0
1m ago17 / 0 / 0

DES

About Viridian Therapeutics, Inc.

Yahoo Finance profile

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 252
Headquarters: Waltham, MA, United States
Website: viridiantherapeutics.com
Officers: Mr. Stephen F. Mahoney J.D., MBA CEO, President & Director
Mr. Seth Harmon Chief Financial Officer
Mr. Thomas W. Beetham J.D., MBA Chief Operating Officer

SEAS

Seasonality · VRDN

2014–2026 · monthly returns

Strongest month Jan +28.80%Weakest month Aug −8.27%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	6.0	-11.0	-33.4	-31.1	30.7	4.3	3.0	22.4	-11.1	-11.1			−41.2%
2025	1.1	-19.9	-13.2	0.5	2.7	0.4	25.3	4.9	17.4	9.5	35.3	-2.6	+62.3%
2024	-11.6	-2.8	-6.4	-24.3	-9.9	8.9	29.5	-12.9	55.0	-5.2	-0.1	-11.0	−12.0%
2023	25.0	-10.3	-22.3	10.2	-15.0	-0.2	-21.1	-3.1	-15.6	-18.5	33.9	30.1	−25.4%
2022	1.7	-10.1	2.3	-25.6	-11.3	-5.2	14.4	67.7	-7.7	-3.0	27.0	15.6	+47.7%
2021	8.3	-7.7	1.6	9.2	-1.3	1.6	-15.1	-13.8	22.9	10.0	6.3	2.8	+20.2%
2020	264.6	-57.5	-40.0	39.5	58.7	12.5	0.0	-16.6	-16.3	69.0	-10.2	-6.7	+128.5%
2019	-5.6	-2.1	-0.4	5.0	-19.1	-13.5	-2.4	-42.5	-36.4	-11.8	24.0	-40.0	−84.2%
2018	-28.1	-26.0	26.3	-2.1	3.1	-9.3	5.1	-7.9	-10.1	-22.6	-19.4	-12.9	−70.9%
2017	81.0	44.5	-5.1	3.8	-15.4	18.4	5.8	-34.2	1.7	-9.5	-3.7	30.9	+108.2%
2016	-26.5	3.6	-10.5	27.5	-9.2	-28.0	15.3	-4.1	6.4	-28.2	76.4	-47.3	−55.3%
2015	6.9	-0.5	-20.4	-12.1	-4.2	21.0	-28.8	-13.5	-31.4	-10.4	28.9	-30.1	−70.6%
2014							-16.0	-23.3	-0.9	-28.9	-9.4	-12.4	−64.0%

INSD

Insider Activity · VRDN

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

1.23M shares

Sells, 6 months

14.2K shares

Net shares

+1.21M

Net change in insider shares

−118.80%

Date	Insider	Transaction	Shares	Value
Aug 18, 2026	Tousignant JenniferOfficer	Sale at price 24.50 per share.	14.2K	$348.19K
Aug 18, 2026	Tousignant JenniferOfficer	Conversion of Exercise of derivative security at price 14.41 per share.	10K	$144.10K
Aug 13, 2026	Tripuraneni RadhikaOfficer	Conversion of Exercise of derivative security at price 13.21 per share.	40K	$528.40K
May 10, 2026	Fairmount Funds Management LlcBeneficial Owner of more than 10% of a Class of Security	Purchase at price 17.00 per share.	1.18M	$20.00M
Mar 2, 2026	Mahoney Stephen FChief Executive Officer	—	18.4K	—
Mar 2, 2026	Harmon SethChief Financial Officer	—	6.3K	—
Mar 2, 2026	Harmon SethChief Financial Officer	—	6.3K	—
Mar 2, 2026	Tousignant JenniferOfficer	—	5.2K	—
Mar 2, 2026	Beetham Thomas WChief Operating Officer	—	9.4K	—
Dec 30, 2025	Tousignant JenniferOfficer	Sale at price 31.16 per share.	2.3K	$70.80K
Oct 22, 2025	Fairmount Funds Management LlcDirector and Beneficial Owner of more than 10% of a Class of Security	Purchase at price 22.00 per share.	454.5K	$10.00M
Jun 9, 2025	Fairmount Funds Management LlcBeneficial Owner of more than 10% of a Class of Security	Conversion of Exercise of derivative security at price 7.80 - 12.31 per share.	14.1K	$166.35K

13F

Investors Holding VRDN

latest 13F filings of 29 followed managers

Investors holding VRDN
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$14.1M	0.02%	768.60K	+278%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

VRDN

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

VRDN

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Viridian Therapeutics, Inc.

Seasonality · VRDN

Insider Activity · VRDN

Congress Trades · VRDN

Investors Holding VRDN

Investors Holding VRDN

Congress Trades · VRDN

Seasonality · VRDN

Insider Activity · VRDN

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Viridian Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News